Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

2021 Year in Review - Multiple Myeloma

Multiple Myeloma

18-Month Analysis of the Phase 3 ANDROMEDA Study of Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain Amyloidosis

Multiple Myeloma

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a BCMA x CD3 Bispecific Antibody, in RRMM

Multiple Myeloma

Updated Results of the KarMMa Trial of Idecabtagene Vicleucel CAR T-Cell Therapy in Patients with RRMM

Multiple Myeloma

Multiple Myeloma Year in Review Introduction

Multiple Myeloma

Updates from the Phase 3 ICARIA-MM Study of Isatuximab plus Pomalidomide/Low-Dose Dexamethasone versus Pomalidomide/Low-Dose Dexamethasone in RRMM

Multiple Myeloma

COVID-19 Vaccine Responsiveness in Patients with MM and Waldenström Macroglobulinemia

Multiple Myeloma

Iberdomide plus Dexamethasone and Daratumumab, Bortezomib, or Carfilzomib in Patients with RRMM

Multiple Myeloma

CARDAMON Trial Results of Carfilzomib Maintenance Following Transplantation or Carfilzomib/Cyclophosphamide/Dexamethasone Consolidation for NDMM

Multiple Myeloma

MAIA Trial Results of Daratumumab, Lenalidomide, and Dexamethasone versus Lenalidomide and Dexamethasone in NDMM

Multiple Myeloma

Updated Results from CARTITUDE-2 Trial of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Patients with Progressive MM After 1 to 3 Previous Lines of Therapy

Page 2 of 3
Results 11 - 20 of 26